08:00 , Nov 13, 2000 |  BC Week In Review  |  Company News

Cardiogene, Intracardia Inc. deal

Cardiogene and Intracardia merged to form Cardion, which will specialize in cardiovascular disease and cell transplantation. Cardiogene will combine its gene therapy technology with Intracardia's cell differentiation and graft enhancement technology. Cardion's most advanced product...
08:00 , Nov 9, 2000 |  BC Extra  |  Top Story

MediGene and Cardiogene buy in U.S.

Two mergers of U.S. and European companies were announced Thursday, both of which will have headquarters in Europe. MediGene (NMarkt:MDG), a cardiovascular and cancer company, will acquire NeuroVir Therapeutics (San Diego, Calif.), which specializes in...
07:00 , Sep 27, 1999 |  BioCentury  |  Finance

Neuer Markt angst

Germany's love affair with high-tech, high-growth companies may be going off the boil. Evotec BioSystems AG last week pulled its planned Neuer Markt IPO, along with four other market hopefuls in high tech, citing poor...
07:00 , Sep 7, 1999 |  BC Week In Review  |  Company News

Genteric management update

Genteric Inc., Alameda, Calif.   Business: Gene/Cell therapy, Drug delivery   Hired: Martin Cleary as president and CEO, formerly president and CEO of CardioGene Therapeutics Inc.  ...
08:00 , Jan 4, 1999 |  BC Week In Review  |  Company News

Atlantic Pharmaceuticals Inc. board of directors update

Atlantic Pharmaceuticals Inc. (ATLC), Raleigh, N.C.   Business: Autoimmune/Inflammation, Cardiovascular, Ophthalmic   Appointed: Martin Cleary, co-founder of CardioGene Therapeutics Inc. and a pharmaceutical consultant  ...
07:00 , Oct 5, 1998 |  BioCentury  |  Politics, Policy & Law

German biotech crosses party lines

German biotech crosses party lines StateGoverning parties # cos Leading lights Baden Wurttemberg Christian Democrat Union 37 LION bioscience, BASF-Lynx, BIG Biotech, CellGenix, Metabion N Rhine Westphalia Social Democrat/Green 28 Qiagen, Artemis, CardioGene, Greentech, NewLab...
07:00 , Jul 6, 1998 |  BC Week In Review  |  Company News

CardioGene Therapeutics Inc., Boston Scientific deal

Boston Scientific acquired CardioGene, a developer of gene expression vectors and site-specific delivery systems for cardiovascular diseases (see BioCentury, Sept. 29, 1997). CardioGene Therapeutics Inc. , Princeton, N.J.   Boston Scientific Corp. , Natick, Mass....
08:00 , Mar 2, 1998 |  BioCentury  |  Tools & Techniques

Making angiogenesis work for the heart

Within a few years, if all goes well, patients with heart disease could have an alternative to the invasive procedures that are the norm for many today. Researchers are publishing the first clinical results using...
07:00 , Sep 29, 1997 |  BioCentury  |  Emerging Company Profile

CardioGene Therapeutics Inc.

CardioGene Therapeutics Inc. Princeton, N.J. Technology: Gene therapy and site-specific delivery devices Disease focus: Cardiovascular disease Clinical status: Preclinical Founded: 1997 by Gary Nabel, Elizabeth Nabel, Jeffrey Leiden and Martin Cleary Corporate partners: None University...
07:00 , Sep 29, 1997 |  BioCentury  |  Emerging Company Profile

Ins and Outs of cardiovascular gene therapy; CardioGene: The Inside; Eurogene: The outside

Gene therapy has two critical requirements: delivery of the gene vector to the appropriate tissues or location within the body, and expression of a gene product that has therapeutic benefit. Cardiovascular disease is thought to...